Induction of tolerance to human factor VIII in mice.
This paper reports loss of human factor VIII (hFVIII) inhibitory antibody in immunocompetent C57BL/6 mice. High-titer anti-hFVIII antibody developed in the mice within 7 to 14 days of intraportal administration of adeno-associated virus (AAV) carrying FVIII that coincided with a reduction in plasma hFVIII antigen. Bethesda titers (> 100 units) persisted relatively unchanged for 9 to 10 months. Unexpectedly, at 10 months after injection of the virus, hFVIII protein (up to 59 ng/mL) was detected in 3 mice at the same time as disappearance of hFVIII inhibitor. The level of hFVIII was similar to that found in immunodeficient mice receiving the same dose of recombinant AAV carrying hFVIII without hFVIII inhibitor. These results suggest that tolerance to hFVIII can be induced by sustained expression of hFVIII in a mouse model. Further elucidation of this observation may affect use of FVIII gene transfer in the treatment of inhibitor-positive patients with hemophilia A.
Chao
H
H
University of North Carolina Gene Therapy Center and the Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Walsh
C E
CE
D000818:Animals; D000906:Antibodies / Q000097:blood*; D000229:Dependovirus / Q000235:genetics; D005169:Factor VIII / Q000032:analysis / Q000235:genetics / Q000276:immunology*; D015870:Gene Expression; D005822:Genetic Vectors; D006801:Humans; D007108:Immune Tolerance; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD; D018345:Mice, Knockout; D016513:Mice, SCID; D011994:Recombinant Proteins / Q000008:administration & dosage
D000906:Antibodies; D011994:Recombinant Proteins; D005169:Factor VIII